FDA Draws Regulatory Line Between Moxduo, HIV Combos
HIV products often increase potency in combination, agency says.
You may also be interested in...
Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.
Morphine/oxycodone fixed-dose product must offer efficacy or safety advantage over individual drug components because the two opioids are not generally used together to treat acute pain, agency says; QRxPharma fails to convince advisory committee that respiratory safety advantage exists.
In search of evidence of a respiratory safety benefit with the two-opioid combination product, FDA agreed to consider exploratory and post hoc analyses from a safety study that failed its primary endpoint.